NAS:CDXC (USA) Also trade in: Germany

ChromaDex Corp

$ 4.09 -0.02 (-0.49%)
Volume: 44,973 Avg Vol (1m): 174,422
Market Cap $: 227.09 Mil Enterprise Value $: 208.22 Mil
P/E (TTM): 0.00 P/B: 10.80
Earnings Power Value -2.19
Net Current Asset Value 0.25
Tangible Book 0.35
Projected FCF -1.47
Median P/S Value 4.42
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 74.14
Cash-To-Debt ranked higher than
51.58% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
CDXC: 74.14
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.56, Med: 6.06, Max: 10000
Current: 74.14
0.56
10000
Equity-to-Asset 0.50
Equity-to-Asset ranked higher than
69.20% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
CDXC: 0.5
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.26, Med: 0.53, Max: 0.86
Current: 0.5
0.26
0.86
Debt-to-Equity 0.01
Debt-to-Equity ranked higher than
97.80% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
CDXC: 0.01
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.01, Med: 0.06, Max: 1.42
Current: 0.01
0.01
1.42
Debt-to-EBITDA -0.01
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
CDXC: -0.01
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -3.19, Med: -0.13, Max: -0.01
Current: -0.01
-3.19
-0.01
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.94
DISTRESS
GREY
SAFE
Beneish M-Score -3.59
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -634.11%
WACC 8.72%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -94.60
Operating Margin ranked higher than
53.03% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
CDXC: -94.6
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -105.12, Med: -38.3, Max: -11.55
Current: -94.6
-105.12
-11.55
Net Margin % -94.78
Net Margin ranked higher than
55.18% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
CDXC: -94.78
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -105.57, Med: -39.35, Max: -13.51
Current: -94.78
-105.57
-13.51
ROE % -98.42
ROE ranked lower than
55.71% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
CDXC: -98.42
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -355.87, Med: -75.42, Max: -35.66
Current: -98.42
-355.87
-35.66
ROA % -68.96
ROA ranked lower than
56.18% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
CDXC: -68.96
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -152.39, Med: -44.9, Max: -15.21
Current: -68.96
-152.39
-15.21
ROC (Joel Greenblatt) % -813.82
ROC (Joel Greenblatt) ranked higher than
56.95% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
CDXC: -813.82
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1027.47, Med: -204.67, Max: -47.6
Current: -813.82
-1027.47
-47.6
3-Year Total Revenue Growth Rate 20.80
3-Year Revenue Growth Rate ranked higher than
53.61% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
CDXC: 4.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 3.2, Max: 24
Current: 4.8
0
24
3-Year Total EBITDA Growth Rate -165.10
3-Year EBITDA Growth Rate ranked lower than
81.55% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
CDXC: -130.5
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -143.4, Med: -22.4, Max: 48.6
Current: -130.5
-143.4
48.6
3-Year EPS w/o NRI Growth Rate -105.80
3-Year EPS w/o NRI Growth Rate ranked lower than
86.24% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
CDXC: -105.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -146.6, Med: -19.7, Max: 43.6
Current: -105.8
-146.6
43.6

» CDXC's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CDXC

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325411    SIC : 2833
Compare WAR:SLV NAS:VRCA XKLS:7090 TSE:2183 BOM:512529 XPAR:ALPHA AMEX:XXII XTER:MDG1 NAS:MTEM SHSE:603139 NAS:NVAX LSE:BVXP XBRU:CYAD NAS:CALA NAS:SBBP NAS:CDMO OTCPK:ABVC XTAE:KMDA NAS:ZYNE NAS:KALA
Traded in other countries OCD1.Germany
Address 10005 Muirlands Boulevard, Suite G, Irvine, CA, USA, 92618
ChromaDex Corp is a natural products company. The company discovers, acquires, develops and commercializes patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. Its product and service portfolio consists of proprietary ingredients, analytical and chemistry based services, regulatory consulting services and natural product fine chemicals. It is organized into three segments: Ingredients, Core Standards, and Contract Services, Scientific and Regulatory Consulting segment.

Ratios

Current vs industry vs history
PB Ratio 10.80
PB Ratio ranked lower than
58.84% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
CDXC: 10.8
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.46, Med: 13.73, Max: 69.44
Current: 10.8
2.46
69.44
PS Ratio 6.43
PS Ratio ranked higher than
56.47% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
CDXC: 6.43
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.19, Med: 6.96, Max: 103.45
Current: 6.43
1.19
103.45
EV-to-EBIT -6.31
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
CDXC: -6.31
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -1392.4, Med: -18.8, Max: -2.2
Current: -6.31
-1392.4
-2.2
EV-to-EBITDA -6.46
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
CDXC: -6.46
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -557.8, Med: -20.1, Max: 960
Current: -6.46
-557.8
960
EV-to-Revenue 5.93
EV-to-Revenue ranked higher than
60.96% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
CDXC: 5.93
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1, Med: 7.3, Max: 102.2
Current: 5.93
1
102.2
Current Ratio 2.24
Current Ratio ranked higher than
56.05% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
CDXC: 2.24
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.33, Med: 2.12, Max: 11
Current: 2.24
0.33
11
Quick Ratio 1.68
Quick Ratio ranked higher than
54.75% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
CDXC: 1.68
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.33, Med: 1.25, Max: 11
Current: 1.68
0.33
11
Days Inventory 154.46
Days Inventory ranked lower than
68.61% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
CDXC: 154.46
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 79.87, Med: 161.96, Max: 260.41
Current: 154.46
79.87
260.41
Days Sales Outstanding 55.32
Days Sales Outstanding ranked lower than
53.29% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
CDXC: 55.32
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 30.14, Med: 46.9, Max: 98.59
Current: 55.32
30.14
98.59
Days Payable 211.66
Days Payable ranked higher than
72.95% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
CDXC: 211.66
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 40.67, Med: 130.31, Max: 224.81
Current: 211.66
40.67
224.81

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -15.20
3-Year Share Buyback Rate ranked lower than
54.61% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
CDXC: -15.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -55.9, Med: -15.9, Max: -2.5
Current: -15.2
-55.9
-2.5

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 11.69
Price-to-Tangible-Book ranked lower than
51.34% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
CDXC: 11.69
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 5.1, Med: 16.64, Max: 66.18
Current: 11.69
5.1
66.18
Price-to-Median-PS-Value 0.93
Price-to-Median-PS-Value ranked lower than
64.90% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
CDXC: 0.93
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.17, Med: 0.99, Max: 11.14
Current: 0.93
0.17
11.14
Earnings Yield (Joel Greenblatt) % -15.88
Earnings Yield (Greenblatt) ranked lower than
56.24% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
CDXC: -15.88
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -44.8, Med: -5.3, Max: -0.1
Current: -15.88
-44.8
-0.1

More Statistics

Revenue (TTM) (Mil) $ 35.04
EPS (TTM) $ -0.61
Beta 1.1
Volatility % 40.04
52-Week Range $ 2.79 - 5
Shares Outstanding (Mil) 55.52

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N